Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001948275 | SCV002201831 | benign | Fanconi anemia | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002266062 | SCV002547843 | uncertain significance | not specified | 2022-05-18 | criteria provided, single submitter | clinical testing | Variant summary: FANCA c.2266C>T (p.Arg756Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00012 in 211904 control chromosomes, predominantly at a frequency of 0.00091 within the South Asian subpopulation in the gnomAD database. This frequency is not higher than estimated maximum expected for a pathogenic variant in FANCA causing Fanconi Anemia (0.0022), allowing no conclusion about variant significance. The variant, c.2266C>T, has been reported in the literature in homozygous state in an individual affected with Fanconi Anemia (Kimble_2018). The authors of this study also reported experimental evidence evaluating an impact on protein function, and demonstrated that the R756C variant protein did not fully complement FANCA-null cells, and it was expressed very poorly and although it was localized to the nucleus, staining was weak (Kimble_2018). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |
Fulgent Genetics, |
RCV002507601 | SCV002814862 | uncertain significance | Fanconi anemia complementation group A | 2022-05-04 | criteria provided, single submitter | clinical testing |